Home » Stocks » Athenex

Athenex, Inc. (ATNX)

Stock Price: $11.94 USD 0.11 (0.93%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.10B
Revenue (ttm) 140.83M
Net Income (ttm) -116.37M
Shares Out 91.73M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $11.94
Previous Close $11.83
Change ($) 0.11
Change (%) 0.93%
Day's Open 11.87
Day's Range 11.79 - 12.13
Day's Volume 461,749
52-Week Range 5.63 - 18.35

More Stats

Market Cap 1.10B
Enterprise Value 1.07B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 91.73M
Float 73.73M
EPS (basic) -1.45
EPS (diluted) -1.46
FCF / Share -1.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.73M
Short Ratio 6.32
Short % of Float 13.20%
Beta 0.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.78
PB Ratio 8.32
Revenue 140.83M
Operating Income -102.77M
Net Income -116.37M
Free Cash Flow -143.00M
Net Cash 21.26M
Net Cash / Share 0.23
Gross Margin -35.05%
Operating Margin -72.97%
Profit Margin -82.60%
FCF Margin -101.54%
ROA -20.67%
ROE -80.40%
ROIC -71.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$28.46*
(138.36% upside)
Low
16.7
Current: $11.94
High
38.0
Target: 28.46
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue10189.1038.0420.5513.94
Revenue Growth13.61%134.21%85.12%47.38%-
Gross Profit31.6142.1012.920.830.79
Operating Income-120-127-110-85.75-50.71
Net Income-124-117-131-87.72-50.60
Shares Outstanding74.0564.5949.9640.1233.77
Earnings Per Share-1.67-1.82-2.63-2.19-1.50
Operating Cash Flow-97.46-109-81.51-47.87-33.76
Capital Expenditures-13.57-3.32-5.44-1.15-3.31
Free Cash Flow-111-113-86.95-49.02-37.07
Cash & Equivalents16110751.0441.7554.03
Total Debt63.8846.761.9833.013.65
Net Cash / Debt96.9460.6649.068.7450.38
Assets310231140106120
Liabilities13410249.6971.2220.90
Book Value18813990.0433.8198.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Athenex, Inc.
Country United States
Employees 574
CEO Yiu Nam Lau

Stock Information

Ticker Symbol ATNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ATNX
IPO Date June 14, 2017

Description

Athenex, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.